Skip to content

Clinical trials

Observational Liver Neoplasms trials in Italy

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Liver Neoplasms Phase: Observational Country / region: Italy Clear all

25 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20041
20081
20091
20101
20111
20121
20162
20171
20184
20194
20202
20211
20241
20263

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed11
Recruiting5
Not yet recruiting3
Active, not recruiting2
Enrolling by invitation2
Unknown status2

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Bayer3
Fondazione Policlinico Universitario Agostino Gemelli IRCCS3
University of Milan3
IRCCS Azienda Ospedaliero-Universitaria di Bologna2
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)1
Azienda USL Toscana Centro1
Catholic University of the Sacred Heart1
European Hepatocellular Cancer Liver Transplant Group1
Fondazione Poliambulanza Istituto Ospedaliero1
Francesco De Cobelli1

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Liver Neoplasms25
Carcinoma, Hepatocellular11
Fibrosis4
Cholangiocarcinoma2
Diabetes Mellitus2
Esophageal Neoplasms2
Fatty Liver2
Gallbladder Neoplasms2
Kidney Neoplasms2
Liver Diseases2

Trials

Showing 1 to 25 of 25. Each trial links to its page on Pharma Observatory.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.